Genmab A/S
NASDAQ:GMAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.45
32.77
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Genmab A/S
Wall Street
Price Targets
GMAB Price Targets Summary
Genmab A/S
According to Wall Street analysts, the average 1-year price target for
GMAB
is 35.12 USD
with a low forecast of 4.85 USD and a high forecast of 71.62 USD.
GMAB Last Price Targets
Genmab A/S
The latest public price target was made on Sep 4, 2024 by
Vikram Purohit
from
Morgan Stanley
,
who expects
GMAB
stock to
rise by 50%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Vikram Purohit
Morgan Stanley
|
31
USD
Upside 50% |
2 months ago
Sep 4, 2024
|
Morgan Stanley Resumes Genmab A/S (GMAB) at Equalweight
StreetInsider
|
Etzer Darout
BMO Capital
|
46
USD
Upside 123% |
3 months ago
Aug 9, 2024
|
Genmab A/S (GMAB) PT Lowered to $46 at BMO Capital
StreetInsider
|
|
Kaveri Pohlman
BTIG
|
47
USD
Upside 128% |
4 months ago
Jun 27, 2024
|
Genmab price target raised to $47 from $46 at BTIG
TheFly
|
|
Raghuram Selvaraju
H.C. Wainwright
|
50
USD
Upside 142% |
4 months ago
Jun 27, 2024
|
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
StreetInsider
|
Asthika Goonewardene
Truist Financial
|
53
USD
Upside 157% |
5 months ago
Jun 4, 2024
|
Genmab price target raised to $53 from $50 at Truist
TheFly
|
|
Unknown Analyst
Leerink Partners
|
36
USD
Upside 74% |
1 year ago
Feb 6, 2023
|
SVB Leerink Maintains Market Perform on Genmab, Raises Price Target to $36
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is GMAB's stock price target?
Price Target
35.12
USD
According to Wall Street analysts, the average 1-year price target for
GMAB
is 35.12 USD
with a low forecast of 4.85 USD and a high forecast of 71.62 USD.
What is Genmab A/S's Revenue forecast?
Projected CAGR
20%
For the last 8 years the
compound annual growth rate for
Genmab A/S's revenue is
40%.
The projected
CAGR
for the next 3 years is
20%.
What is Genmab A/S's Operating Income forecast?
Projected CAGR
24%
For the last 8 years the
compound annual growth rate for
Genmab A/S's operating income is
28%.
The projected
CAGR
for the next 3 years is
24%.
What is Genmab A/S's Net Income forecast?
Projected CAGR
22%
For the last 8 years the
compound annual growth rate for
Genmab A/S's net income is
24%.
The projected
CAGR
for the next 3 years is
22%.
You don't have any saved screeners yet
